266 related articles for article (PubMed ID: 34370877)
1. Experimental models of Barth syndrome.
Pu WT
J Inherit Metab Dis; 2022 Jan; 45(1):72-81. PubMed ID: 34370877
[TBL] [Abstract][Full Text] [Related]
2. Clinical presentation and natural history of Barth Syndrome: An overview.
Taylor C; Rao ES; Pierre G; Chronopoulou E; Hornby B; Heyman A; Vernon HJ
J Inherit Metab Dis; 2022 Jan; 45(1):7-16. PubMed ID: 34355402
[TBL] [Abstract][Full Text] [Related]
3. Genetic modifiers modulate phenotypic expression of tafazzin deficiency in a mouse model of Barth syndrome.
Wang S; Yazawa E; Keating EM; Mazumdar N; Hauschild A; Ma Q; Wu H; Xu Y; Shi X; Strathdee D; Gerszten RE; Schlame M; Pu WT
Hum Mol Genet; 2023 Jun; 32(12):2055-2067. PubMed ID: 36917259
[TBL] [Abstract][Full Text] [Related]
4. Cardiolipin function in the yeast S. cerevisiae and the lessons learned for Barth syndrome.
Ji J; Greenberg ML
J Inherit Metab Dis; 2022 Jan; 45(1):60-71. PubMed ID: 34626131
[TBL] [Abstract][Full Text] [Related]
5. The lipid environment modulates cardiolipin and phospholipid constitution in wild type and tafazzin-deficient cells.
Oemer G; Koch J; Wohlfarter Y; Lackner K; Gebert REM; Geley S; Zschocke J; Keller MA
J Inherit Metab Dis; 2022 Jan; 45(1):38-50. PubMed ID: 34494285
[TBL] [Abstract][Full Text] [Related]
6. Barth syndrome: cardiolipin, cellular pathophysiology, management, and novel therapeutic targets.
Zegallai HM; Hatch GM
Mol Cell Biochem; 2021 Mar; 476(3):1605-1629. PubMed ID: 33415565
[TBL] [Abstract][Full Text] [Related]
7. Decreased pyruvate dehydrogenase activity in Tafazzin-deficient cells is caused by dysregulation of pyruvate dehydrogenase phosphatase 1 (PDP1).
Liang Z; Ralph-Epps T; Schmidtke MW; Kumar V; Greenberg ML
J Biol Chem; 2024 Mar; 300(3):105697. PubMed ID: 38301889
[TBL] [Abstract][Full Text] [Related]
8. Barth Syndrome: Connecting Cardiolipin to Cardiomyopathy.
Ikon N; Ryan RO
Lipids; 2017 Feb; 52(2):99-108. PubMed ID: 28070695
[TBL] [Abstract][Full Text] [Related]
9. TAZ encodes tafazzin, a transacylase essential for cardiolipin formation and central to the etiology of Barth syndrome.
Garlid AO; Schaffer CT; Kim J; Bhatt H; Guevara-Gonzalez V; Ping P
Gene; 2020 Feb; 726():144148. PubMed ID: 31647997
[TBL] [Abstract][Full Text] [Related]
10. Tafazzin Mutation Affecting Cardiolipin Leads to Increased Mitochondrial Superoxide Anions and Mitophagy Inhibition in Barth Syndrome.
Petit PX; Ardilla-Osorio H; Penalvia L; Rainey NE
Cells; 2020 Oct; 9(10):. PubMed ID: 33096711
[TBL] [Abstract][Full Text] [Related]
11. The Function of Tafazzin, a Mitochondrial Phospholipid-Lysophospholipid Acyltransferase.
Schlame M; Xu Y
J Mol Biol; 2020 Aug; 432(18):5043-5051. PubMed ID: 32234310
[TBL] [Abstract][Full Text] [Related]
12. Barth syndrome: cellular compensation of mitochondrial dysfunction and apoptosis inhibition due to changes in cardiolipin remodeling linked to tafazzin (TAZ) gene mutation.
Gonzalvez F; D'Aurelio M; Boutant M; Moustapha A; Puech JP; Landes T; Arnauné-Pelloquin L; Vial G; Taleux N; Slomianny C; Wanders RJ; Houtkooper RH; Bellenguer P; Møller IM; Gottlieb E; Vaz FM; Manfredi G; Petit PX
Biochim Biophys Acta; 2013 Aug; 1832(8):1194-206. PubMed ID: 23523468
[TBL] [Abstract][Full Text] [Related]
13. Cardiolipin Remodeling Defects Impair Mitochondrial Architecture and Function in a Murine Model of Barth Syndrome Cardiomyopathy.
Zhu S; Chen Z; Zhu M; Shen Y; Leon LJ; Chi L; Spinozzi S; Tan C; Gu Y; Nguyen A; Zhou Y; Feng W; Vaz FM; Wang X; Gustafsson AB; Evans SM; Kunfu O; Fang X
Circ Heart Fail; 2021 Jun; 14(6):e008289. PubMed ID: 34129362
[TBL] [Abstract][Full Text] [Related]
14. Cardiolipin remodeling in Barth syndrome and other hereditary cardiomyopathies.
Bertero E; Kutschka I; Maack C; Dudek J
Biochim Biophys Acta Mol Basis Dis; 2020 Aug; 1866(8):165803. PubMed ID: 32348916
[TBL] [Abstract][Full Text] [Related]
15. Barth Syndrome Cardiomyopathy: An Update.
Pang J; Bao Y; Mitchell-Silbaugh K; Veevers J; Fang X
Genes (Basel); 2022 Apr; 13(4):. PubMed ID: 35456462
[TBL] [Abstract][Full Text] [Related]
16. SS-31 treatment ameliorates cardiac mitochondrial morphology and defective mitophagy in a murine model of Barth syndrome.
Russo S; De Rasmo D; Rossi R; Signorile A; Lobasso S
Sci Rep; 2024 Jun; 14(1):13655. PubMed ID: 38871974
[TBL] [Abstract][Full Text] [Related]
17. Identification of novel mitochondrial localization signals in human Tafazzin, the cause of the inherited cardiomyopathic disorder Barth syndrome.
Dinca AA; Chien WM; Chin MT
J Mol Cell Cardiol; 2018 Jan; 114():83-92. PubMed ID: 29129703
[TBL] [Abstract][Full Text] [Related]
18. Loss of tafazzin results in decreased myoblast differentiation in C2C12 cells: A myoblast model of Barth syndrome and cardiolipin deficiency.
Lou W; Reynolds CA; Li Y; Liu J; Hüttemann M; Schlame M; Stevenson D; Strathdee D; Greenberg ML
Biochim Biophys Acta Mol Cell Biol Lipids; 2018 Aug; 1863(8):857-865. PubMed ID: 29694924
[TBL] [Abstract][Full Text] [Related]
19. Barth syndrome cells display widespread remodeling of mitochondrial complexes without affecting metabolic flux distribution.
Chatzispyrou IA; Guerrero-Castillo S; Held NM; Ruiter JPN; Denis SW; IJlst L; Wanders RJ; van Weeghel M; Ferdinandusse S; Vaz FM; Brandt U; Houtkooper RH
Biochim Biophys Acta Mol Basis Dis; 2018 Nov; 1864(11):3650-3658. PubMed ID: 30251684
[TBL] [Abstract][Full Text] [Related]
20. Expression of human monolysocardiolipin acyltransferase-1 improves mitochondrial function in Barth syndrome lymphoblasts.
Mejia EM; Zegallai H; Bouchard ED; Banerji V; Ravandi A; Hatch GM
J Biol Chem; 2018 May; 293(20):7564-7577. PubMed ID: 29563154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
